Chinese Cephalexin market was steady in the first half of November after a 0.4% price increase in October. Inventory was balanced in Shanghai and production at major facilities was uninterrupted, providing supply for both domestic and export demand. Feedstock cost including 7-ACA intermediates was stable, which helped to control production cost and reduce volatility. Port operation and logistics was smooth and Cephalexin flow was unimpeded. Pharmaceutical demand, especially for respiratory and urinary infection treatment was steady. Despite the early stability, market is expecting a slight price decline in the latter half of November. International demand is weakening, overseas buyers are cautious and supply is ample, which will slow down export and put mild pressure on prices. Asian suppliers will compete with each other to retain market share. Overall market is cautious and price will be soft in the short term while domestic flow is steady.
